CLINICAL EFFICACY & VARIOUS TREATMENTS OF SENSORINEURAL HEARING LOSS AND ITS ASSOCIATION WITH METABOLIC SYNDROME

This research article aims to analyze the clinical efficiency of several medical therapies to treat sensorineural hearing loss. Association of sensorineural hearing loss and metabolic syndrome is shown. Hearing defeat is increasing at an exponential rate. Damage to human sensory hair cells and SGNs is usually permanent. It is treated with a variety of medical therapy. DNA coding for a neurotrophic protein is transferred into cochlear cells when electricity is applied. The circular window of cochlea is being studied for pharmaceutical supply. SGNs are protected against degeneration by their slow-release and high-payload medication delivery capabilities. A novel viral vector and gene-editing technique have restored hearing in mice with genetic hearing loss. SGN repopulation and neurotrophin supply, as well as hearing loss, have all been investigated. These and other developments in pharmaceutical treatment will facilitate the translation of pre-clinical results into clinical trials. Hearing loss is considered a complication of metabolic syndrome. Hearing loss is more likely in those with metabolic syndrome